SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Politics for Pros- moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
Recommended by:
Maurice Winn
To: frankw1900 who wrote (722666)7/31/2020 9:04:46 PM
From: skinowski1 Recommendation  Read Replies (2) of 794011
 
Hey Frank, I think that large beautiful bridge you have for sale isn’t over Hudson, it’s over the East River. Other than that, we’re in agreement :)

Of course, they would say they don’t believe that the medication works - so, until proven, there isn’t an ethical dilemma. I think one solution would be to refrain from taking the double blind path, using placebo - and simply use as controls those patients who refuse HCQ. With enough numbers, the results would be plenty significant.

You’re right - at this point, I wouldn’t be comfortable giving placebo to people who would have chosen HCQ.

It’s true - double blind randomized placebo controlled trials are the gold standard - but it’s not the only standard.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News